OM Quote, Financials, Valuation and Earnings

Integra Lifesciences Holdings has a net margin of -87.01% compared to Outset Medical's net margin of 4.39%. Outset Medical's return on equity of -178.08% beat Integra Lifesciences Holdings's return on equity of -0.45%.

Outset Medical has a consensus price target of $37.50, signalling upside risk potential of 243.72%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $26.25 which suggests that it could grow by 21.47%. Given that Outset Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Outset Medical is more attractive than Integra Lifesciences Holdings.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.241, suggesting its more volatile than the S&P 500 by 24.12%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.5M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $442.6M. Outset Medical's net income of -$25.6M is lower than Integra Lifesciences Holdings's net income of $19.4M. Notably, Outset Medical's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.33x versus 1.03x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies has a net margin of -87.01% compared to Outset Medical's net margin of -0.81%. Outset Medical's return on equity of -178.08% beat iRhythm Technologies's return on equity of -100.75%.

Outset Medical has a consensus price target of $37.50, signalling upside risk potential of 243.72%. On the other hand iRhythm Technologies has an analysts' consensus of $133.00 which suggests that it could grow by 24.44%. Given that Outset Medical has higher upside potential than iRhythm Technologies, analysts believe Outset Medical is more attractive than iRhythm Technologies.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.450, suggesting its more volatile than the S&P 500 by 44.979%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.5M, which are smaller than iRhythm Technologies quarterly revenues of $164.3M. Outset Medical's net income of -$25.6M is lower than iRhythm Technologies's net income of -$1.3M. Notably, Outset Medical's price-to-earnings ratio is -- while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.33x versus 5.63x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -87.01% compared to Outset Medical's net margin of -1226.82%. Outset Medical's return on equity of -178.08% beat VolitionRX's return on equity of --.

Outset Medical has a consensus price target of $37.50, signalling upside risk potential of 243.72%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 550.47%. Given that VolitionRX has higher upside potential than Outset Medical, analysts believe VolitionRX is more attractive than Outset Medical.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.5M, which are larger than VolitionRX quarterly revenues of $474.5K. Outset Medical's net income of -$25.6M is lower than VolitionRX's net income of -$5.8M. Notably, Outset Medical's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.33x versus 33.47x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -87.01% compared to Outset Medical's net margin of -10.04%. Outset Medical's return on equity of -178.08% beat Xtant Medical Holdings's return on equity of -35.34%.

Outset Medical has a consensus price target of $37.50, signalling upside risk potential of 243.72%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 272.26%. Given that Xtant Medical Holdings has higher upside potential than Outset Medical, analysts believe Xtant Medical Holdings is more attractive than Outset Medical.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.5M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Outset Medical's net income of -$25.6M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Outset Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.33x versus 0.54x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.